Open AccessPerioperative pharmacotherapy for endoprosthetics: potential of chondroitin sulfate and glucosamine sulfate
Author(s) -
I. Yu. Torshin,
Т. Б. Минасов,
N. V. Zagorodniy,
А. М. Лила,
О. А. Gromova
Publication year - 2022
Publication title -
farmakoèkonomika
Language(s) - English
Resource type - Journals
eISSN - 2070-4933
pISSN - 2070-4909
DOI - 10.17749/2070-4909/farmakoekonomika.2022.136
Subject(s) - chondroitin sulfate , osteoarthritis , pharmacotherapy , medicine , perioperative , glucosamine , rehabilitation , pharmacology , anesthesia , surgery , physical therapy , chemistry , biochemistry , pathology , alternative medicine , anatomy , glycosaminoglycan
Joint endoprosthetics is a treatment of choice for patients with decompensated osteoarthritis (OA), who have exhausted the possibilities of pharmacotherapy and other methods of conservative treatment. Preparation for endoprosthetics and rehabilitation after surgery usually includes measures to improve the muscle condition and local blood circulation in the joint area, and if necessary, pain management. The unique spectrum of anti-inflammatory effect of chondroprotectors based on chondroitin sulfate and glucosamine sulfate includes inhibition of NF-κB cascade, toll-like receptors, pro-inflammatory cytokines, metalloproteinases, and significantly alleviates the course of OA. Reducing the severity of OA is important for preparing for surgery, subsequent rehabilitation, and preventing the revision surgery.